Cord blood transplants: a new hope for Hard-to-Treat blood diseases?
NCT ID NCT03016806
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This study is testing whether umbilical cord blood stem cells from unrelated donors can safely and effectively restore blood cell production in people with serious conditions like leukemia, immune deficiencies, and inherited blood disorders. The main goal is to see how quickly the new cells start working (engraftment) and how often the transplant fails. Researchers are also tracking side effects like graft-versus-host disease, where donor cells attack the patient's body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wilmot Cancer Institute
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
umbilical cord blood stem cells
What this could lead to
If successful, this could improve the success rate of cord blood transplants for people with serious blood or immune disorders, offering a potential path to disease control.
What could go wrong
This is a small, early-phase study (30 participants) focused on feasibility and safety. The transplant may fail to engraft, or patients may develop severe graft-versus-host disease, a serious complication.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.